Cargando…
Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders
The T-cell lymphoproliferative disorders are a heterogeneous group of non-Hodgkin’s lymphomas (NHL) for which current therapeutic strategies are inadequate, as most patients afflicted with these NHL will succumb to disease progression within 2 years of diagnosis. Appreciation of the genetic and immu...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170899/ https://www.ncbi.nlm.nih.gov/pubmed/28031823 http://dx.doi.org/10.1186/s40425-016-0201-6 |
_version_ | 1782483851716591616 |
---|---|
author | Phillips, Tycel Devata, Sumana Wilcox, Ryan A. |
author_facet | Phillips, Tycel Devata, Sumana Wilcox, Ryan A. |
author_sort | Phillips, Tycel |
collection | PubMed |
description | The T-cell lymphoproliferative disorders are a heterogeneous group of non-Hodgkin’s lymphomas (NHL) for which current therapeutic strategies are inadequate, as most patients afflicted with these NHL will succumb to disease progression within 2 years of diagnosis. Appreciation of the genetic and immunologic landscape of these aggressive NHL, including PD-L1 (B7-H1, CD274) expression by malignant T cells and within the tumor microenvironment, provides a strong rationale for therapeutic targeting this immune checkpoint. While further studies are needed, the available data suggests that responses with PD-1 checkpoint blockade alone will unlikely approach those achieved in other lymphoproliferative disorders. Herein, we review the unique challenges posed by the T-cell lymphoproliferative disorders and discuss potential strategies to optimize checkpoint blockade in these T-cell derived malignancies. |
format | Online Article Text |
id | pubmed-5170899 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-51708992016-12-28 Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders Phillips, Tycel Devata, Sumana Wilcox, Ryan A. J Immunother Cancer Review The T-cell lymphoproliferative disorders are a heterogeneous group of non-Hodgkin’s lymphomas (NHL) for which current therapeutic strategies are inadequate, as most patients afflicted with these NHL will succumb to disease progression within 2 years of diagnosis. Appreciation of the genetic and immunologic landscape of these aggressive NHL, including PD-L1 (B7-H1, CD274) expression by malignant T cells and within the tumor microenvironment, provides a strong rationale for therapeutic targeting this immune checkpoint. While further studies are needed, the available data suggests that responses with PD-1 checkpoint blockade alone will unlikely approach those achieved in other lymphoproliferative disorders. Herein, we review the unique challenges posed by the T-cell lymphoproliferative disorders and discuss potential strategies to optimize checkpoint blockade in these T-cell derived malignancies. BioMed Central 2016-12-20 /pmc/articles/PMC5170899/ /pubmed/28031823 http://dx.doi.org/10.1186/s40425-016-0201-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Phillips, Tycel Devata, Sumana Wilcox, Ryan A. Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders |
title | Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders |
title_full | Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders |
title_fullStr | Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders |
title_full_unstemmed | Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders |
title_short | Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders |
title_sort | challenges and opportunities for checkpoint blockade in t-cell lymphoproliferative disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170899/ https://www.ncbi.nlm.nih.gov/pubmed/28031823 http://dx.doi.org/10.1186/s40425-016-0201-6 |
work_keys_str_mv | AT phillipstycel challengesandopportunitiesforcheckpointblockadeintcelllymphoproliferativedisorders AT devatasumana challengesandopportunitiesforcheckpointblockadeintcelllymphoproliferativedisorders AT wilcoxryana challengesandopportunitiesforcheckpointblockadeintcelllymphoproliferativedisorders |